Medical Doctor Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Manasi Hulyalkar

Obesity Medicine Fenton, MO Medical Doctor

NPI 1467803098 CMS profile 2725677

1203 Smizer Mill Rd Ste 108, Fenton, MO 63026

Open in the dashboard

General payments

$831

33 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Manasi Hulyalkar of Fenton, MO is reported in the CMS Open Payments database as having received $831 across 33 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $340 19
2024 General $257 7
2023 General $193 4
2021 General $15 1
2020 General $26 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Manasi Hulyalkar
  • Missouri median
  • Middle half of Missouri
  • National median

In program year 2025, general payments to Manasi Hulyalkar were reported at $340. Among 20,470 Missouri profiles paid that year, the median was $164 and the middle half received between $50 and $619.

Show as a table
Year Manasi Hulyalkar Missouri median Middle half National median
2019 $0 $176 $52–$688 $163
2020 $26 $117 $36–$411 $114
2021 $15 $136 $37–$511 $132
2022 $0 $147 $42–$555 $149
2023 $193 $158 $46–$594 $160
2024 $257 $159 $47–$595 $164
2025 $340 $164 $50–$619 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. Novo Nordisk Inc $329 6 payments
  2. Corium, Inc. $171 11 payments
  3. Rhythm Pharmaceuticals, Inc. $109 5 payments
  4. AstraZeneca Pharmaceuticals LP $41 3 payments
  5. Soleno Therapeutics, Inc. $37 1 payment
  6. Bayer HealthCare Pharmaceuticals Inc. $33 1 payment
  7. GlaxoSmithKline, LLC. $23 1 payment
  8. Sanofi Pasteur Inc. $23 1 payment
  9. Collegium Pharmaceutical, Inc. $17 1 payment
  10. Vertical Pharmaceuticals, LLC $17 1 payment
  11. Other $32 2 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Food and Beverage $799 32 payments
  2. Education $32 1 payment
Products named General payments · program years 2020–2025
  1. Wegovy $316 5 payments
  2. Azstarys $171 11 payments
  3. Imcivree $109 5 payments
  4. FARXIGA $41 3 payments
  5. VYKAT XR $37 1 payment
  6. Kerendia $33 1 payment
  7. BEXSERO $23 1 payment
  8. PENMENVY $23 1 payment
  9. BEYFORTUS $23 1 payment
  10. Jornay PM $17 1 payment
  11. Other $61 4 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

33 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Obesity Medicine in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record